| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Transglutaminases | 48 | 2017 | 67 | 6.560 |
Why?
|
| GTP-Binding Proteins | 14 | 2017 | 231 | 3.040 |
Why?
|
| Factor XIII | 29 | 2012 | 31 | 2.650 |
Why?
|
| Heparin | 18 | 2019 | 205 | 1.940 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 15 | 2017 | 50 | 1.880 |
Why?
|
| Hematology | 2 | 2020 | 10 | 1.450 |
Why?
|
| Blood Coagulation | 12 | 2020 | 123 | 1.360 |
Why?
|
| Fibrin | 22 | 2008 | 35 | 1.300 |
Why?
|
| Fibrinogen | 23 | 2020 | 87 | 1.260 |
Why?
|
| Thrombocytopenia | 9 | 2019 | 122 | 1.260 |
Why?
|
| Thrombin | 21 | 2015 | 117 | 1.050 |
Why?
|
| Anticoagulants | 10 | 2019 | 356 | 1.010 |
Why?
|
| Venous Thromboembolism | 3 | 2017 | 116 | 0.970 |
Why?
|
| Venous Thrombosis | 3 | 2019 | 124 | 0.810 |
Why?
|
| Thrombophilia | 2 | 2019 | 21 | 0.800 |
Why?
|
| Guanosine Triphosphate | 11 | 2013 | 65 | 0.800 |
Why?
|
| Education, Medical, Graduate | 2 | 2020 | 214 | 0.790 |
Why?
|
| Platelet Activation | 2 | 2019 | 24 | 0.750 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 2 | 2017 | 45 | 0.740 |
Why?
|
| Alternative Splicing | 2 | 2013 | 93 | 0.730 |
Why?
|
| Calcium | 11 | 2013 | 929 | 0.710 |
Why?
|
| Nitric Oxide | 3 | 2017 | 382 | 0.710 |
Why?
|
| Medical Oncology | 1 | 2020 | 110 | 0.700 |
Why?
|
| Factor V | 1 | 2019 | 20 | 0.700 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 127 | 0.700 |
Why?
|
| Cardiopulmonary Bypass | 7 | 2020 | 250 | 0.670 |
Why?
|
| Teaching | 1 | 2020 | 169 | 0.670 |
Why?
|
| Humans | 111 | 2021 | 68525 | 0.660 |
Why?
|
| Enzyme Inhibitors | 4 | 2010 | 659 | 0.630 |
Why?
|
| Hematologic Diseases | 1 | 2017 | 20 | 0.620 |
Why?
|
| Factor XIII Deficiency | 2 | 2019 | 3 | 0.620 |
Why?
|
| Advisory Committees | 1 | 2018 | 73 | 0.620 |
Why?
|
| Hemostasis | 5 | 2007 | 32 | 0.600 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 281 | 0.580 |
Why?
|
| von Willebrand Diseases | 4 | 2000 | 11 | 0.580 |
Why?
|
| Neutrophils | 1 | 2017 | 204 | 0.580 |
Why?
|
| Biogenic Amines | 1 | 2016 | 15 | 0.580 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2016 | 284 | 0.570 |
Why?
|
| Protein Aggregation, Pathological | 1 | 2016 | 13 | 0.570 |
Why?
|
| Blood Platelets | 12 | 2001 | 284 | 0.550 |
Why?
|
| Histamine | 2 | 2013 | 52 | 0.530 |
Why?
|
| Cardiac Surgical Procedures | 5 | 2020 | 450 | 0.530 |
Why?
|
| Clinical Competence | 1 | 2020 | 657 | 0.520 |
Why?
|
| Platelet Factor 4 | 4 | 2019 | 10 | 0.520 |
Why?
|
| Physicians | 1 | 2017 | 324 | 0.480 |
Why?
|
| Leukemia, Monocytic, Acute | 2 | 2012 | 9 | 0.470 |
Why?
|
| Peptide Fragments | 7 | 2007 | 483 | 0.460 |
Why?
|
| Hypesthesia | 1 | 2012 | 4 | 0.450 |
Why?
|
| Chin | 1 | 2012 | 5 | 0.440 |
Why?
|
| Protein Conformation | 9 | 2001 | 362 | 0.430 |
Why?
|
| Platelet Aggregation | 12 | 2001 | 127 | 0.410 |
Why?
|
| Prothrombin | 3 | 1998 | 12 | 0.410 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2004 | 376 | 0.390 |
Why?
|
| Blood Coagulation Disorders | 5 | 2019 | 45 | 0.390 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2019 | 507 | 0.380 |
Why?
|
| Succinimides | 1 | 2010 | 11 | 0.370 |
Why?
|
| Kinetics | 18 | 2001 | 1047 | 0.370 |
Why?
|
| Phosphorylcholine | 2 | 2001 | 12 | 0.360 |
Why?
|
| Acetates | 1 | 2010 | 74 | 0.350 |
Why?
|
| Vascular Diseases | 2 | 2007 | 94 | 0.350 |
Why?
|
| Blood Loss, Surgical | 4 | 2020 | 79 | 0.350 |
Why?
|
| Inflammation | 2 | 2013 | 1030 | 0.340 |
Why?
|
| Wound Healing | 5 | 2013 | 260 | 0.340 |
Why?
|
| Sphingosine | 4 | 2001 | 315 | 0.340 |
Why?
|
| Glycoproteins | 4 | 1991 | 238 | 0.340 |
Why?
|
| Aspirin | 3 | 2010 | 295 | 0.330 |
Why?
|
| Thrombosis | 6 | 1997 | 218 | 0.330 |
Why?
|
| Recombinant Proteins | 10 | 2013 | 742 | 0.330 |
Why?
|
| Magnesium | 3 | 1998 | 110 | 0.310 |
Why?
|
| Antithrombin III | 6 | 2015 | 23 | 0.310 |
Why?
|
| GTP Phosphohydrolases | 2 | 1997 | 46 | 0.300 |
Why?
|
| Leukocytes | 1 | 2007 | 99 | 0.300 |
Why?
|
| Blood Coagulation Tests | 6 | 2020 | 31 | 0.300 |
Why?
|
| Antifibrinolytic Agents | 5 | 2019 | 52 | 0.300 |
Why?
|
| Blood Transfusion | 3 | 2019 | 205 | 0.300 |
Why?
|
| Blood Platelet Disorders | 3 | 2000 | 4 | 0.290 |
Why?
|
| Molecular Sequence Data | 11 | 2007 | 1446 | 0.290 |
Why?
|
| Substrate Specificity | 7 | 2016 | 234 | 0.290 |
Why?
|
| Neovascularization, Physiologic | 4 | 2007 | 164 | 0.280 |
Why?
|
| Neoplasms | 2 | 2017 | 1660 | 0.280 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 2007 | 317 | 0.280 |
Why?
|
| Oligopeptides | 7 | 2005 | 152 | 0.270 |
Why?
|
| Liver Cirrhosis | 2 | 2019 | 301 | 0.270 |
Why?
|
| Middle Aged | 24 | 2021 | 21119 | 0.270 |
Why?
|
| Amino Acid Sequence | 9 | 2007 | 1082 | 0.270 |
Why?
|
| Factor VIII | 3 | 1996 | 27 | 0.270 |
Why?
|
| Peptides | 2 | 2004 | 455 | 0.260 |
Why?
|
| Adenosine Triphosphate | 6 | 2002 | 314 | 0.250 |
Why?
|
| Binding Sites | 11 | 1999 | 631 | 0.250 |
Why?
|
| Animals | 23 | 2016 | 20877 | 0.250 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2004 | 17 | 0.250 |
Why?
|
| Cell Adhesion | 2 | 2017 | 324 | 0.250 |
Why?
|
| Repetitive Sequences, Amino Acid | 1 | 2004 | 6 | 0.250 |
Why?
|
| Models, Molecular | 4 | 2013 | 546 | 0.250 |
Why?
|
| Heart Diseases | 1 | 2007 | 276 | 0.240 |
Why?
|
| Endothelial Cells | 1 | 2007 | 384 | 0.240 |
Why?
|
| Hemorrhage | 6 | 2019 | 328 | 0.240 |
Why?
|
| Female | 33 | 2021 | 38015 | 0.240 |
Why?
|
| Plasma | 3 | 2019 | 58 | 0.240 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 9 | 2004 | 272 | 0.230 |
Why?
|
| Thrombelastography | 2 | 2020 | 19 | 0.230 |
Why?
|
| Cross-Linking Reagents | 6 | 1999 | 80 | 0.230 |
Why?
|
| Hemorheology | 2 | 2007 | 3 | 0.220 |
Why?
|
| Liver | 6 | 1993 | 1118 | 0.220 |
Why?
|
| Glycosaminoglycans | 3 | 1992 | 88 | 0.220 |
Why?
|
| von Willebrand Factor | 3 | 2015 | 47 | 0.210 |
Why?
|
| Blood Coagulation Factors | 7 | 2019 | 44 | 0.210 |
Why?
|
| Adult | 21 | 2020 | 21375 | 0.210 |
Why?
|
| Skin | 3 | 2007 | 451 | 0.210 |
Why?
|
| Molecular Weight | 8 | 2005 | 358 | 0.210 |
Why?
|
| Guinea Pigs | 8 | 2001 | 124 | 0.210 |
Why?
|
| Factor VIIa | 2 | 2011 | 25 | 0.210 |
Why?
|
| Immunoblotting | 7 | 2004 | 254 | 0.210 |
Why?
|
| Aged | 19 | 2021 | 14842 | 0.200 |
Why?
|
| S-Nitrosothiols | 1 | 2001 | 1 | 0.200 |
Why?
|
| Mercaptoethanol | 1 | 2001 | 4 | 0.200 |
Why?
|
| Breast Neoplasms | 6 | 2005 | 1533 | 0.200 |
Why?
|
| Autoanalysis | 1 | 2001 | 11 | 0.200 |
Why?
|
| Fibrinolysis | 4 | 2000 | 55 | 0.200 |
Why?
|
| Algorithms | 3 | 2020 | 1194 | 0.200 |
Why?
|
| Factor XIIIa | 4 | 2008 | 4 | 0.200 |
Why?
|
| Protein Binding | 9 | 1999 | 1027 | 0.200 |
Why?
|
| Sickle Cell Trait | 1 | 2021 | 24 | 0.190 |
Why?
|
| Postoperative Hemorrhage | 1 | 2001 | 69 | 0.190 |
Why?
|
| Platelet Function Tests | 1 | 2000 | 10 | 0.190 |
Why?
|
| Anemia, Sickle Cell | 3 | 2015 | 364 | 0.190 |
Why?
|
| Blood Proteins | 2 | 1991 | 94 | 0.190 |
Why?
|
| Biomarkers, Tumor | 1 | 2004 | 508 | 0.190 |
Why?
|
| Adenosine Diphosphate | 5 | 2001 | 66 | 0.190 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2000 | 69 | 0.180 |
Why?
|
| Monitoring, Intraoperative | 1 | 2020 | 53 | 0.180 |
Why?
|
| Hospitals, University | 1 | 2000 | 169 | 0.180 |
Why?
|
| Peptide Hydrolases | 6 | 2015 | 82 | 0.180 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2000 | 32 | 0.180 |
Why?
|
| Antibodies, Monoclonal | 6 | 2008 | 510 | 0.180 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2000 | 61 | 0.180 |
Why?
|
| Trypsin | 5 | 1997 | 64 | 0.180 |
Why?
|
| Time Factors | 8 | 2018 | 4655 | 0.180 |
Why?
|
| Cell Division | 2 | 2000 | 541 | 0.180 |
Why?
|
| Coronary Artery Bypass | 4 | 1997 | 218 | 0.180 |
Why?
|
| Whole Blood Coagulation Time | 3 | 2020 | 8 | 0.170 |
Why?
|
| Antithrombins | 3 | 2019 | 32 | 0.170 |
Why?
|
| Colorectal Neoplasms | 1 | 2004 | 560 | 0.170 |
Why?
|
| Coronary Disease | 1 | 2021 | 358 | 0.170 |
Why?
|
| Tertiary Care Centers | 1 | 2019 | 67 | 0.170 |
Why?
|
| Prospective Studies | 9 | 2020 | 3702 | 0.170 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 4843 | 0.170 |
Why?
|
| Inservice Training | 1 | 2019 | 68 | 0.170 |
Why?
|
| Lymph Nodes | 1 | 2000 | 258 | 0.170 |
Why?
|
| Unnecessary Procedures | 1 | 2019 | 49 | 0.170 |
Why?
|
| Male | 27 | 2021 | 37281 | 0.160 |
Why?
|
| Protein Structure, Tertiary | 2 | 2010 | 322 | 0.160 |
Why?
|
| Neoplasm Invasiveness | 1 | 1999 | 369 | 0.160 |
Why?
|
| Fibrinolysin | 4 | 1991 | 33 | 0.160 |
Why?
|
| Autoantibodies | 4 | 1990 | 434 | 0.160 |
Why?
|
| Biomarkers | 5 | 2019 | 1593 | 0.160 |
Why?
|
| Endothelium, Vascular | 3 | 2001 | 371 | 0.160 |
Why?
|
| Molecular Structure | 2 | 2010 | 397 | 0.160 |
Why?
|
| Biotin | 3 | 2007 | 28 | 0.160 |
Why?
|
| RNA, Transfer, Amino Acyl | 1 | 1997 | 3 | 0.160 |
Why?
|
| Platelet Count | 6 | 2020 | 100 | 0.160 |
Why?
|
| Nucleotides | 1 | 1998 | 29 | 0.160 |
Why?
|
| Neurodegenerative Diseases | 2 | 2013 | 102 | 0.160 |
Why?
|
| Calibration | 1 | 1998 | 73 | 0.160 |
Why?
|
| Education, Medical, Continuing | 1 | 2019 | 136 | 0.160 |
Why?
|
| Acid Anhydride Hydrolases | 1 | 1996 | 13 | 0.150 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2019 | 185 | 0.150 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1054 | 0.150 |
Why?
|
| Amines | 3 | 2007 | 98 | 0.150 |
Why?
|
| Adenosine Triphosphatases | 1 | 1996 | 83 | 0.150 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating) | 1 | 2016 | 1 | 0.140 |
Why?
|
| Amination | 1 | 2016 | 4 | 0.140 |
Why?
|
| Huntingtin Protein | 1 | 2016 | 5 | 0.140 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2016 | 28 | 0.140 |
Why?
|
| Immunoglobulin G | 1 | 2019 | 481 | 0.140 |
Why?
|
| Hematocrit | 3 | 2019 | 70 | 0.140 |
Why?
|
| Curriculum | 1 | 2020 | 575 | 0.140 |
Why?
|
| Protein Domains | 1 | 2016 | 74 | 0.140 |
Why?
|
| Risk Factors | 6 | 2017 | 5719 | 0.140 |
Why?
|
| Mutagenesis, Site-Directed | 4 | 1999 | 204 | 0.140 |
Why?
|
| Acute Kidney Injury | 1 | 2019 | 232 | 0.140 |
Why?
|
| Macromolecular Substances | 4 | 2004 | 122 | 0.140 |
Why?
|
| Inpatients | 1 | 2017 | 208 | 0.140 |
Why?
|
| Education, Medical | 1 | 2017 | 147 | 0.140 |
Why?
|
| Disease Management | 1 | 2018 | 248 | 0.140 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 503 | 0.140 |
Why?
|
| Cytoskeletal Proteins | 1 | 2016 | 108 | 0.130 |
Why?
|
| Histones | 1 | 2016 | 111 | 0.130 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2016 | 144 | 0.130 |
Why?
|
| Dermatan Sulfate | 2 | 1992 | 12 | 0.130 |
Why?
|
| Heparitin Sulfate | 2 | 1992 | 20 | 0.130 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1995 | 32 | 0.130 |
Why?
|
| Chondroitin Sulfates | 2 | 1992 | 44 | 0.130 |
Why?
|
| Quality Improvement | 1 | 2019 | 413 | 0.130 |
Why?
|
| In Vitro Techniques | 9 | 2000 | 765 | 0.130 |
Why?
|
| Putrescine | 4 | 2004 | 17 | 0.120 |
Why?
|
| Point Mutation | 1 | 1994 | 97 | 0.120 |
Why?
|
| Fibrinolytic Agents | 4 | 1991 | 377 | 0.120 |
Why?
|
| Signal Transduction | 3 | 2016 | 2688 | 0.120 |
Why?
|
| Postoperative Complications | 6 | 2013 | 1615 | 0.120 |
Why?
|
| Immunoassay | 3 | 2008 | 64 | 0.120 |
Why?
|
| Escherichia coli | 4 | 1999 | 368 | 0.120 |
Why?
|
| Lysine | 4 | 2005 | 96 | 0.120 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 2264 | 0.120 |
Why?
|
| Preoperative Care | 5 | 2005 | 275 | 0.120 |
Why?
|
| Plasminogen Activators | 2 | 1991 | 19 | 0.110 |
Why?
|
| Heparinoids | 2 | 1992 | 3 | 0.110 |
Why?
|
| Urokinase-Type Plasminogen Activator | 2 | 1991 | 26 | 0.110 |
Why?
|
| Arthritis, Rheumatoid | 2 | 1991 | 155 | 0.110 |
Why?
|
| Polymorphism, Genetic | 2 | 2012 | 301 | 0.110 |
Why?
|
| Bone Marrow Transplantation | 2 | 1990 | 149 | 0.110 |
Why?
|
| Blood Component Transfusion | 1 | 2012 | 11 | 0.110 |
Why?
|
| Daunorubicin | 1 | 2012 | 20 | 0.110 |
Why?
|
| Chemistry Techniques, Analytical | 1 | 1992 | 8 | 0.110 |
Why?
|
| Cytarabine | 1 | 2012 | 44 | 0.110 |
Why?
|
| Blood Cells | 2 | 1994 | 27 | 0.110 |
Why?
|
| Aorta | 4 | 2007 | 316 | 0.110 |
Why?
|
| Hemorrhagic Disorders | 2 | 1989 | 7 | 0.110 |
Why?
|
| Translocation, Genetic | 1 | 2012 | 74 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2012 | 77 | 0.110 |
Why?
|
| Genetic Markers | 1 | 2012 | 144 | 0.110 |
Why?
|
| Cations, Divalent | 4 | 2001 | 27 | 0.110 |
Why?
|
| Drug Resistance | 1 | 2013 | 223 | 0.110 |
Why?
|
| Enzyme Activation | 4 | 2002 | 791 | 0.110 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2012 | 82 | 0.110 |
Why?
|
| Immunohistochemistry | 5 | 2001 | 1174 | 0.100 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 2798 | 0.100 |
Why?
|
| Cyclophosphamide | 3 | 1993 | 129 | 0.100 |
Why?
|
| Autoimmunity | 1 | 2013 | 118 | 0.100 |
Why?
|
| Liver Failure | 1 | 2011 | 27 | 0.100 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2013 | 130 | 0.100 |
Why?
|
| Synovial Membrane | 1 | 1991 | 23 | 0.100 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2013 | 135 | 0.100 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2013 | 146 | 0.100 |
Why?
|
| Thrombolytic Therapy | 2 | 1992 | 233 | 0.100 |
Why?
|
| Sequence Alignment | 3 | 2007 | 165 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 1996 | 772 | 0.100 |
Why?
|
| Liver Failure, Acute | 1 | 2011 | 49 | 0.100 |
Why?
|
| Antibodies | 2 | 2005 | 241 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2002 | 64 | 0.100 |
Why?
|
| Osteoarthritis | 1 | 1991 | 73 | 0.100 |
Why?
|
| Vitronectin | 4 | 1991 | 12 | 0.100 |
Why?
|
| International Normalized Ratio | 3 | 2019 | 23 | 0.100 |
Why?
|
| Protamines | 3 | 2001 | 14 | 0.100 |
Why?
|
| Epinephrine | 2 | 2001 | 103 | 0.090 |
Why?
|
| Intensive Care Units | 1 | 2013 | 344 | 0.090 |
Why?
|
| Models, Biological | 2 | 2008 | 981 | 0.090 |
Why?
|
| Dextrans | 1 | 1990 | 33 | 0.090 |
Why?
|
| Structure-Activity Relationship | 4 | 2002 | 420 | 0.090 |
Why?
|
| Rats | 7 | 2002 | 5300 | 0.090 |
Why?
|
| Macrophages | 4 | 1999 | 647 | 0.090 |
Why?
|
| Umbilical Veins | 2 | 2007 | 54 | 0.090 |
Why?
|
| Rats, Inbred F344 | 5 | 2002 | 104 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 1990 | 467 | 0.090 |
Why?
|
| Acetylation | 1 | 2010 | 94 | 0.090 |
Why?
|
| Collagen | 4 | 2002 | 636 | 0.090 |
Why?
|
| Transforming Growth Factor beta | 3 | 2002 | 384 | 0.090 |
Why?
|
| Leukemia, Plasma Cell | 1 | 1989 | 6 | 0.090 |
Why?
|
| Terbium | 1 | 1989 | 5 | 0.090 |
Why?
|
| Machado-Joseph Disease | 1 | 2008 | 1 | 0.080 |
Why?
|
| Octoxynol | 1 | 2008 | 19 | 0.080 |
Why?
|
| Tyrphostins | 1 | 2008 | 13 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 1745 | 0.080 |
Why?
|
| Amyloidosis | 1 | 1989 | 48 | 0.080 |
Why?
|
| Naphthoquinones | 1 | 2008 | 14 | 0.080 |
Why?
|
| Combinatorial Chemistry Techniques | 1 | 2008 | 25 | 0.080 |
Why?
|
| Cattle | 4 | 2001 | 475 | 0.080 |
Why?
|
| Predictive Value of Tests | 4 | 2019 | 1465 | 0.080 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2008 | 60 | 0.080 |
Why?
|
| Young Adult | 2 | 2017 | 5708 | 0.080 |
Why?
|
| Biotinylation | 2 | 2007 | 27 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 137 | 0.080 |
Why?
|
| Incidence | 3 | 2021 | 1582 | 0.080 |
Why?
|
| Hypoprothrombinemias | 1 | 1987 | 1 | 0.080 |
Why?
|
| Drosophila melanogaster | 1 | 2008 | 80 | 0.080 |
Why?
|
| Cell Line | 3 | 2007 | 1752 | 0.080 |
Why?
|
| Bernard-Soulier Syndrome | 1 | 1987 | 1 | 0.080 |
Why?
|
| Epitopes | 1 | 1988 | 146 | 0.080 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 1987 | 19 | 0.080 |
Why?
|
| Intracellular Fluid | 1 | 2007 | 24 | 0.080 |
Why?
|
| HL-60 Cells | 1 | 2007 | 50 | 0.080 |
Why?
|
| Catalysis | 2 | 2004 | 123 | 0.080 |
Why?
|
| Prednisone | 1 | 1987 | 104 | 0.080 |
Why?
|
| Vimentin | 1 | 2007 | 47 | 0.080 |
Why?
|
| Vasodilation | 1 | 2007 | 85 | 0.070 |
Why?
|
| Capillary Permeability | 1 | 2007 | 69 | 0.070 |
Why?
|
| Carotid Arteries | 1 | 2007 | 110 | 0.070 |
Why?
|
| Thromboplastin | 4 | 1991 | 21 | 0.070 |
Why?
|
| Glutamine | 1 | 1986 | 45 | 0.070 |
Why?
|
| Renal Insufficiency | 1 | 2007 | 121 | 0.070 |
Why?
|
| Pulmonary Embolism | 1 | 2008 | 253 | 0.070 |
Why?
|
| Isoenzymes | 1 | 2007 | 308 | 0.070 |
Why?
|
| Skin Diseases | 1 | 2007 | 122 | 0.070 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 1997 | 230 | 0.070 |
Why?
|
| Extracellular Matrix | 2 | 2002 | 493 | 0.070 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2007 | 282 | 0.070 |
Why?
|
| Thrombophlebitis | 3 | 1990 | 47 | 0.070 |
Why?
|
| Adolescent | 2 | 2017 | 8903 | 0.070 |
Why?
|
| Cytokines | 2 | 2000 | 866 | 0.070 |
Why?
|
| Polymers | 4 | 1988 | 244 | 0.060 |
Why?
|
| Factor XII Deficiency | 2 | 1997 | 5 | 0.060 |
Why?
|
| Prothrombin Time | 3 | 2011 | 24 | 0.060 |
Why?
|
| Leucovorin | 1 | 2004 | 35 | 0.060 |
Why?
|
| Atherosclerosis | 1 | 2007 | 204 | 0.060 |
Why?
|
| Aminocaproic Acid | 2 | 1997 | 12 | 0.060 |
Why?
|
| Bevacizumab | 1 | 2004 | 34 | 0.060 |
Why?
|
| Luminescent Measurements | 2 | 1995 | 58 | 0.060 |
Why?
|
| Myocardial Infarction | 1 | 1989 | 807 | 0.060 |
Why?
|
| Thioredoxins | 1 | 2004 | 26 | 0.060 |
Why?
|
| Solubility | 1 | 2004 | 134 | 0.060 |
Why?
|
| Fluorouracil | 1 | 2004 | 130 | 0.060 |
Why?
|
| Fibrinopeptide A | 3 | 1995 | 4 | 0.060 |
Why?
|
| alpha-2-Antiplasmin | 3 | 2005 | 4 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 1987 | 514 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2004 | 151 | 0.060 |
Why?
|
| Molecular Probes | 2 | 1993 | 27 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2021 | 2356 | 0.060 |
Why?
|
| Cells, Cultured | 3 | 2001 | 2673 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2012 | 7028 | 0.050 |
Why?
|
| Stroke | 1 | 2015 | 2161 | 0.050 |
Why?
|
| Stress, Mechanical | 2 | 2000 | 208 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2004 | 1070 | 0.050 |
Why?
|
| Cartilage, Articular | 1 | 2002 | 38 | 0.050 |
Why?
|
| Pyrroles | 1 | 2002 | 83 | 0.050 |
Why?
|
| Nitroso Compounds | 1 | 2001 | 16 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2002 | 195 | 0.050 |
Why?
|
| Platelet Adhesiveness | 1 | 2001 | 20 | 0.050 |
Why?
|
| Indoles | 1 | 2002 | 146 | 0.050 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2000 | 6 | 0.050 |
Why?
|
| Mice | 3 | 2007 | 8472 | 0.050 |
Why?
|
| Cysteine | 1 | 2001 | 112 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2008 | 2550 | 0.050 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2001 | 48 | 0.050 |
Why?
|
| Hemostatics | 1 | 2001 | 47 | 0.050 |
Why?
|
| Disease Progression | 1 | 2004 | 1037 | 0.050 |
Why?
|
| Myocardium | 1 | 2007 | 1204 | 0.050 |
Why?
|
| Tamoxifen | 1 | 2000 | 62 | 0.050 |
Why?
|
| Monitoring, Physiologic | 2 | 2011 | 219 | 0.050 |
Why?
|
| Blood Viscosity | 1 | 2020 | 9 | 0.050 |
Why?
|
| Glutamates | 2 | 1991 | 41 | 0.050 |
Why?
|
| Carotid Artery Diseases | 1 | 2001 | 83 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 1995 | 1753 | 0.050 |
Why?
|
| Axilla | 1 | 2000 | 36 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2000 | 142 | 0.050 |
Why?
|
| Elasticity | 1 | 2020 | 103 | 0.050 |
Why?
|
| Diffusion Chambers, Culture | 1 | 1999 | 3 | 0.050 |
Why?
|
| North Carolina | 1 | 2000 | 224 | 0.050 |
Why?
|
| Monocytes | 3 | 1989 | 210 | 0.040 |
Why?
|
| Cell Hypoxia | 1 | 2000 | 92 | 0.040 |
Why?
|
| Wounds, Penetrating | 1 | 1999 | 45 | 0.040 |
Why?
|
| Thrombopoietin | 1 | 2019 | 15 | 0.040 |
Why?
|
| Anemia | 1 | 2000 | 104 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2001 | 1737 | 0.040 |
Why?
|
| Transfusion Reaction | 1 | 2019 | 33 | 0.040 |
Why?
|
| Portal Vein | 1 | 2019 | 46 | 0.040 |
Why?
|
| Cicatrix | 1 | 1999 | 60 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2000 | 626 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2000 | 274 | 0.040 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 1999 | 114 | 0.040 |
Why?
|
| Feedback, Psychological | 1 | 2019 | 17 | 0.040 |
Why?
|
| Crystallography, X-Ray | 1 | 1999 | 190 | 0.040 |
Why?
|
| ROC Curve | 1 | 2020 | 392 | 0.040 |
Why?
|
| Factor Xa Inhibitors | 1 | 2019 | 43 | 0.040 |
Why?
|
| Mast Cells | 1 | 1999 | 113 | 0.040 |
Why?
|
| Spectrometry, Fluorescence | 2 | 1989 | 112 | 0.040 |
Why?
|
| Myocardial Ischemia | 1 | 2000 | 172 | 0.040 |
Why?
|
| Vascular Surgical Procedures | 1 | 2000 | 168 | 0.040 |
Why?
|
| Citrates | 1 | 1998 | 7 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 1999 | 852 | 0.040 |
Why?
|
| Chromatography, Affinity | 2 | 1989 | 73 | 0.040 |
Why?
|
| Calcium Chloride | 2 | 1988 | 38 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 109 | 0.040 |
Why?
|
| Hydrolysis | 1 | 1998 | 144 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2000 | 737 | 0.040 |
Why?
|
| Catheters, Indwelling | 1 | 1998 | 72 | 0.040 |
Why?
|
| Exons | 1 | 1997 | 122 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2000 | 1341 | 0.040 |
Why?
|
| Benzimidazoles | 2 | 2013 | 128 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 1997 | 100 | 0.040 |
Why?
|
| Nucleoside-Triphosphatase | 1 | 1996 | 2 | 0.040 |
Why?
|
| Cloning, Molecular | 1 | 1997 | 357 | 0.040 |
Why?
|
| Syndrome | 2 | 2007 | 255 | 0.040 |
Why?
|
| Intraoperative Complications | 2 | 2000 | 129 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 191 | 0.040 |
Why?
|
| Intraoperative Period | 2 | 1994 | 62 | 0.040 |
Why?
|
| Adenosine Monophosphate | 1 | 1996 | 41 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2000 | 3256 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 1999 | 475 | 0.040 |
Why?
|
| In Situ Hybridization | 1 | 1996 | 201 | 0.040 |
Why?
|
| Melanoma | 2 | 1990 | 335 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 1999 | 396 | 0.040 |
Why?
|
| Tissue Distribution | 2 | 1997 | 282 | 0.030 |
Why?
|
| Pregnancy | 2 | 2000 | 2331 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2005 | 2222 | 0.030 |
Why?
|
| Glutathione Transferase | 1 | 1996 | 166 | 0.030 |
Why?
|
| Polytetrafluoroethylene | 1 | 1995 | 55 | 0.030 |
Why?
|
| Densitometry | 1 | 1995 | 15 | 0.030 |
Why?
|
| Colorimetry | 1 | 1995 | 22 | 0.030 |
Why?
|
| Iodine Radioisotopes | 2 | 1985 | 119 | 0.030 |
Why?
|
| Antithrombin III Deficiency | 1 | 1994 | 1 | 0.030 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2015 | 99 | 0.030 |
Why?
|
| Restriction Mapping | 1 | 1994 | 85 | 0.030 |
Why?
|
| Drug Stability | 1 | 1994 | 71 | 0.030 |
Why?
|
| Patient Selection | 1 | 2019 | 592 | 0.030 |
Why?
|
| Blood Specimen Collection | 1 | 1994 | 17 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 1998 | 1046 | 0.030 |
Why?
|
| Coronary Artery Disease | 1 | 2001 | 696 | 0.030 |
Why?
|
| Microchemistry | 1 | 1994 | 19 | 0.030 |
Why?
|
| Goats | 1 | 1994 | 17 | 0.030 |
Why?
|
| Boron Compounds | 1 | 1994 | 21 | 0.030 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 1994 | 8 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2077 | 0.030 |
Why?
|
| Viscera | 1 | 1994 | 16 | 0.030 |
Why?
|
| Serum Albumin, Bovine | 1 | 1994 | 43 | 0.030 |
Why?
|
| Mosaicism | 1 | 1994 | 21 | 0.030 |
Why?
|
| Carmustine | 2 | 1993 | 14 | 0.030 |
Why?
|
| Huntington Disease | 1 | 1994 | 15 | 0.030 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1994 | 37 | 0.030 |
Why?
|
| Lupus Coagulation Inhibitor | 3 | 1990 | 15 | 0.030 |
Why?
|
| Ribosomes | 1 | 1994 | 23 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 503 | 0.030 |
Why?
|
| Blood Vessel Prosthesis | 1 | 1995 | 182 | 0.030 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 1994 | 49 | 0.030 |
Why?
|
| Spermatozoa | 1 | 1994 | 75 | 0.030 |
Why?
|
| Sodium Chloride | 1 | 1994 | 136 | 0.030 |
Why?
|
| Caseins | 1 | 1993 | 19 | 0.030 |
Why?
|
| beta-Alanine | 1 | 2013 | 20 | 0.030 |
Why?
|
| Muscles | 1 | 1994 | 158 | 0.030 |
Why?
|
| Dabigatran | 1 | 2013 | 35 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 1994 | 251 | 0.030 |
Why?
|
| Pyridones | 1 | 2013 | 40 | 0.030 |
Why?
|
| Rivaroxaban | 1 | 2013 | 26 | 0.030 |
Why?
|
| Morpholines | 1 | 2013 | 79 | 0.030 |
Why?
|
| Brain Chemistry | 1 | 1994 | 173 | 0.030 |
Why?
|
| Thiophenes | 1 | 2013 | 76 | 0.030 |
Why?
|
| Reference Values | 1 | 1994 | 579 | 0.030 |
Why?
|
| Biocompatible Materials | 1 | 1995 | 247 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 1994 | 311 | 0.030 |
Why?
|
| Cisplatin | 2 | 1993 | 192 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 766 | 0.030 |
Why?
|
| Contrast Media | 2 | 2007 | 594 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2013 | 411 | 0.030 |
Why?
|
| Phosphorylation | 2 | 1997 | 1199 | 0.030 |
Why?
|
| Arachidonic Acids | 2 | 1989 | 97 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2013 | 190 | 0.030 |
Why?
|
| Base Sequence | 1 | 1994 | 1015 | 0.030 |
Why?
|
| Anesthesia, Epidural | 1 | 1991 | 11 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1991 | 95 | 0.030 |
Why?
|
| Clinical Trials as Topic | 2 | 2013 | 848 | 0.030 |
Why?
|
| Radioligand Assay | 1 | 1991 | 109 | 0.030 |
Why?
|
| Vascular Patency | 1 | 1991 | 122 | 0.030 |
Why?
|
| Keratinocytes | 1 | 1991 | 68 | 0.030 |
Why?
|
| Intracranial Pressure | 1 | 2011 | 58 | 0.030 |
Why?
|
| Analgesia, Epidural | 1 | 1991 | 40 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 1992 | 334 | 0.030 |
Why?
|
| DNA | 1 | 1994 | 597 | 0.020 |
Why?
|
| Latex Fixation Tests | 2 | 1989 | 4 | 0.020 |
Why?
|
| Factor VII Deficiency | 1 | 1990 | 1 | 0.020 |
Why?
|
| Protein C Deficiency | 1 | 1990 | 5 | 0.020 |
Why?
|
| Melphalan | 1 | 1990 | 15 | 0.020 |
Why?
|
| Erythrocyte Membrane | 1 | 1990 | 20 | 0.020 |
Why?
|
| Protein Kinases | 1 | 1991 | 122 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 1991 | 223 | 0.020 |
Why?
|
| Dithiothreitol | 1 | 1990 | 17 | 0.020 |
Why?
|
| Dibutyryl Cyclic GMP | 1 | 1989 | 4 | 0.020 |
Why?
|
| Carcinoma, Small Cell | 1 | 1990 | 53 | 0.020 |
Why?
|
| Genital Neoplasms, Female | 1 | 1990 | 37 | 0.020 |
Why?
|
| Factor VII | 1 | 1989 | 8 | 0.020 |
Why?
|
| Endothelium | 2 | 1987 | 98 | 0.020 |
Why?
|
| Phospholipids | 1 | 1990 | 108 | 0.020 |
Why?
|
| Receptors, Complement | 1 | 1990 | 58 | 0.020 |
Why?
|
| Myocarditis | 1 | 1990 | 49 | 0.020 |
Why?
|
| Dextran Sulfate | 1 | 1990 | 88 | 0.020 |
Why?
|
| Cyclic GMP | 1 | 1989 | 99 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2013 | 7264 | 0.020 |
Why?
|
| Plasma Cells | 1 | 1989 | 19 | 0.020 |
Why?
|
| Lanthanum | 1 | 1989 | 3 | 0.020 |
Why?
|
| Metals, Rare Earth | 1 | 1989 | 2 | 0.020 |
Why?
|
| Phagocytes | 1 | 1988 | 15 | 0.020 |
Why?
|
| Immunochemistry | 1 | 1988 | 17 | 0.020 |
Why?
|
| Binding Sites, Antibody | 1 | 1988 | 34 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 1991 | 332 | 0.020 |
Why?
|
| Research Design | 1 | 2013 | 729 | 0.020 |
Why?
|
| Procainamide | 1 | 1988 | 12 | 0.020 |
Why?
|
| Thermodynamics | 1 | 1988 | 162 | 0.020 |
Why?
|
| Histiocytes | 1 | 2007 | 8 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2007 | 30 | 0.020 |
Why?
|
| Methods | 1 | 1987 | 156 | 0.020 |
Why?
|
| Chemical Phenomena | 1 | 1987 | 62 | 0.020 |
Why?
|
| Ristocetin | 1 | 1987 | 3 | 0.020 |
Why?
|
| Chemistry | 1 | 1987 | 45 | 0.020 |
Why?
|
| Chromatography | 1 | 1987 | 47 | 0.020 |
Why?
|
| Femoral Vein | 1 | 1987 | 15 | 0.020 |
Why?
|
| Antigens | 1 | 1987 | 90 | 0.020 |
Why?
|
| Iliac Vein | 1 | 1987 | 10 | 0.020 |
Why?
|
| Antilymphocyte Serum | 1 | 1987 | 52 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 1988 | 489 | 0.020 |
Why?
|
| Metals | 1 | 1988 | 100 | 0.020 |
Why?
|
| Immunosorbent Techniques | 1 | 1987 | 18 | 0.020 |
Why?
|
| Dimerization | 1 | 2007 | 99 | 0.020 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 1987 | 9 | 0.020 |
Why?
|
| Child | 2 | 2015 | 6400 | 0.020 |
Why?
|
| Affinity Labels | 1 | 1987 | 66 | 0.020 |
Why?
|
| Electrophoresis | 1 | 1987 | 69 | 0.020 |
Why?
|
| Gadolinium | 1 | 2007 | 88 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2007 | 104 | 0.020 |
Why?
|
| Azides | 1 | 1987 | 56 | 0.020 |
Why?
|
| Pre-Eclampsia | 1 | 1989 | 202 | 0.020 |
Why?
|
| Quality Control | 1 | 1987 | 81 | 0.020 |
Why?
|
| Methylamines | 1 | 1986 | 4 | 0.020 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 1987 | 54 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2007 | 230 | 0.020 |
Why?
|
| Transferrin | 1 | 2007 | 94 | 0.020 |
Why?
|
| Partial Thromboplastin Time | 3 | 1992 | 57 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 1988 | 567 | 0.020 |
Why?
|
| Endarterectomy, Carotid | 1 | 2007 | 110 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 1987 | 270 | 0.020 |
Why?
|
| Batroxobin | 1 | 1985 | 1 | 0.020 |
Why?
|
| alpha-Macroglobulins | 1 | 1985 | 8 | 0.020 |
Why?
|
| Plasminogen | 1 | 1985 | 28 | 0.020 |
Why?
|
| Afibrinogenemia | 1 | 1985 | 2 | 0.020 |
Why?
|
| Fibrosis | 1 | 2007 | 371 | 0.020 |
Why?
|
| Carotid Stenosis | 1 | 2007 | 163 | 0.020 |
Why?
|
| Edetic Acid | 1 | 1985 | 29 | 0.020 |
Why?
|
| Biopsy | 1 | 2007 | 539 | 0.020 |
Why?
|
| Chymotrypsin | 1 | 1984 | 11 | 0.020 |
Why?
|
| Spheroids, Cellular | 1 | 2005 | 45 | 0.020 |
Why?
|
| Fibroblasts | 2 | 2007 | 902 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2005 | 48 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 1984 | 165 | 0.020 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2005 | 85 | 0.020 |
Why?
|
| Hot Temperature | 1 | 1985 | 152 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2005 | 384 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2007 | 1548 | 0.010 |
Why?
|
| Length of Stay | 1 | 2005 | 780 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2002 | 99 | 0.010 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2002 | 126 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1990 | 1172 | 0.010 |
Why?
|
| Fibrosarcoma | 1 | 2000 | 21 | 0.010 |
Why?
|
| Cornea | 1 | 2000 | 76 | 0.010 |
Why?
|
| Nitroimidazoles | 1 | 2000 | 1 | 0.010 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2000 | 34 | 0.010 |
Why?
|
| DNA Adducts | 1 | 2000 | 7 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2000 | 30 | 0.010 |
Why?
|
| Endothelial Growth Factors | 1 | 2000 | 25 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 2000 | 28 | 0.010 |
Why?
|
| Lymphokines | 1 | 2000 | 49 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 1849 | 0.010 |
Why?
|
| Models, Animal | 1 | 2000 | 252 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2002 | 954 | 0.010 |
Why?
|
| Arachidonic Acid | 2 | 1989 | 86 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2000 | 261 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2000 | 546 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2000 | 191 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2000 | 219 | 0.010 |
Why?
|
| Receptor, TIE-2 | 1 | 1997 | 4 | 0.010 |
Why?
|
| Rest | 1 | 1997 | 78 | 0.010 |
Why?
|
| Uterus | 1 | 1997 | 77 | 0.010 |
Why?
|
| Blood Vessels | 1 | 1997 | 102 | 0.010 |
Why?
|
| Ovary | 1 | 1997 | 99 | 0.010 |
Why?
|
| Tyrosine | 1 | 1997 | 196 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 1997 | 371 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1997 | 532 | 0.010 |
Why?
|
| Blood | 1 | 1995 | 40 | 0.010 |
Why?
|
| Viscosity | 1 | 1995 | 72 | 0.010 |
Why?
|
| Awards and Prizes | 1 | 1995 | 27 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2002 | 938 | 0.010 |
Why?
|
| Polyethylene Glycols | 1 | 1995 | 149 | 0.010 |
Why?
|
| Basal Ganglia | 1 | 1994 | 45 | 0.010 |
Why?
|
| Muscle Proteins | 1 | 1994 | 94 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1994 | 167 | 0.010 |
Why?
|
| Age of Onset | 1 | 1994 | 188 | 0.010 |
Why?
|
| Acrolein | 1 | 1993 | 9 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1993 | 29 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1994 | 492 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 1994 | 290 | 0.010 |
Why?
|
| Aging | 1 | 1997 | 911 | 0.010 |
Why?
|
| Factor X Deficiency | 1 | 1990 | 1 | 0.010 |
Why?
|
| Factor XI Deficiency | 1 | 1990 | 6 | 0.010 |
Why?
|
| Phlebography | 1 | 1990 | 31 | 0.010 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 1 | 1989 | 41 | 0.010 |
Why?
|
| Prostaglandin Endoperoxides, Synthetic | 1 | 1989 | 52 | 0.010 |
Why?
|
| Thromboxane B2 | 1 | 1989 | 108 | 0.010 |
Why?
|
| Sphingomyelins | 1 | 1989 | 106 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1988 | 47 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1988 | 138 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 1989 | 157 | 0.010 |
Why?
|
| Hydrogen Peroxide | 1 | 1988 | 168 | 0.000 |
Why?
|
| Phorbol 12,13-Dibutyrate | 1 | 1987 | 24 | 0.000 |
Why?
|
| Phorbol Esters | 1 | 1987 | 37 | 0.000 |
Why?
|
| Combined Modality Therapy | 1 | 1990 | 951 | 0.000 |
Why?
|
| Diglycerides | 1 | 1987 | 49 | 0.000 |
Why?
|
| Platelet Activating Factor | 1 | 1987 | 34 | 0.000 |
Why?
|
| Dipyridamole | 1 | 1987 | 26 | 0.000 |
Why?
|
| Lipopolysaccharides | 1 | 1989 | 455 | 0.000 |
Why?
|
| Interferon-gamma | 1 | 1988 | 241 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1994 | 3185 | 0.000 |
Why?
|
| Emergencies | 1 | 1987 | 107 | 0.000 |
Why?
|
| Ceramides | 1 | 1989 | 578 | 0.000 |
Why?
|
| Culture Techniques | 1 | 1983 | 65 | 0.000 |
Why?
|
| Intestinal Mucosa | 1 | 1983 | 219 | 0.000 |
Why?
|
| Kallikreins | 1 | 1983 | 323 | 0.000 |
Why?
|
| Lung | 1 | 1983 | 849 | 0.000 |
Why?
|